- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07600281
Ultra-Processed Foods, Palatability, Appetite, and Gastrointestinal Transit
20. mai 2026 oppdatert av: Richard Mattes, Purdue University
Ultra-Processed Foods - Palatability and Appetite
The goal of this clinical trial is to learn how food processing level affects appetite and gastrointestinal transit time when meal palatability is changed.
Participants will complete one screening visit and four test visits.
During each test visit, participants will consume one of four meals that differ by food processing level and palatability: high-palatability ultra-processed food, low-palatability ultra-processed food, high-palatability non-ultra-processed food, or low-palatability non-ultra-processed food.
The main questions this study aims to answer are whether food processing and palatability affect appetite sensations and gastrointestinal transit time.
Participants will rate appetite sensations during each test visit and provide breath samples to measure gastrointestinal transit time.
Studieoversikt
Status
Fullført
Detaljert beskrivelse
This is a randomized crossover trial examining the effects of food processing level and palatability on appetite and gastrointestinal transit time.
Participants will complete a screening visit followed by four test visits, with each test visit separated by at least one week.
Each participant will consume all four test meals: high-palatability ultra-processed food, low-palatability ultra-processed food, high-palatability non-ultra-processed food, and low-palatability non-ultra-processed food.
Palatability will be reduced by adding bitter melon powder to the low-palatability meals.
During each test visit, participants will consume the assigned test meal containing lactulose as a marker of gastrointestinal transit time.
Breath samples will be collected to assess orocecal transit time using hydrogen analysis.
Participants will also rate meal palatability and appetite sensations, including hunger, fullness, desire to eat, amount they could eat, and thirst, using visual analog scales during the test visit.
Studietype
Intervensjonell
Registrering (Faktiske)
40
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Indiana
-
West Lafayette, Indiana, Forente stater, 47907
- Purdue University
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Individuals aged 18 to 60 years.
- Any sex, gender, or orientation.
- Self-reported good health.
- No medication use.
- No allergies or food sensitivities to any of the foods used in the study.
- No anticipated change in physical activity during the study period.
- Willingness to complete all planned study activities, including the screening visit and four test visits.
- At screening, participants must rate the selected high-palatability foods between 60 and 90 on a 100-unit visual analog scale, where 100 = extremely palatable.
- At screening, participants must rate the selected low-palatability foods between 10 and 40 on a 100-unit visual analog scale.
Exclusion Criteria:
- Younger than 18 years or older than 60 years.
- Current medication use.
- Allergies or food sensitivities to any study foods.
- Not meeting the required palatability rating ranges during screening.
- Anticipated change in physical activity during the study period.
- Not self-reporting good health.
- Unwillingness or inability to complete the planned study activities.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Palatable Ultra-Processed Food
Participants will consume a palatable ultra-processed test meal during one study visit.
The meal will be used to assess appetite sensations, palatability ratings, and gastrointestinal transit time.
|
Participants will consume a palatable ultra-processed test meal during one study visit.
The meal will consist of commonly available ultra-processed food items and will be used to assess appetite sensations, meal palatability, and gastrointestinal transit time.
|
|
Eksperimentell: Unpalatable Ultra-Processed Food
Participants will consume an unpalatable ultra-processed test meal during one study visit.
Palatability will be reduced by adding bitter melon powder.
The meal will be used to assess appetite sensations, palatability ratings, and gastrointestinal transit time.
|
Participants will consume an unpalatable ultra-processed test meal during one study visit.
Palatability will be reduced by adding organic bitter melon powder to the ultra-processed meal.
The meal will be used to assess appetite sensations, meal palatability, and gastrointestinal transit time.
|
|
Eksperimentell: Palatable Non-Ultra-Processed Food
Participants will consume a palatable non-ultra-processed test meal during one study visit.
The meal will be used to assess appetite sensations, palatability ratings, and gastrointestinal transit time.
|
Participants will consume a palatable non-ultra-processed test meal during one study visit.
The meal will consist of commonly available non-ultra-processed food items and will be used to assess appetite sensations, meal palatability, and gastrointestinal transit time.
|
|
Eksperimentell: Unpalatable Non-Ultra-Processed Food
Participants will consume a unpalatable non-ultra-processed test meal during one study visit.
Palatability will be reduced by adding bitter melon powder.
The meal will be used to assess appetite sensations, palatability ratings, and gastrointestinal transit time.
|
Participants will consume an unpalatable non-ultra-processed test meal during one study visit.
Palatability will be reduced by adding organic bitter melon powder to the non-ultra-processed meal.
The meal will be used to assess appetite sensations, meal palatability, and gastrointestinal transit time.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Orocecal Transit Time
Tidsramme: During each test visit, up to 4.5 hours after meal consumption
|
Orocecal transit time will be assessed using hydrogen analysis of end-alveolar breath samples collected after consumption of each test meal.
Each test meal will contain lactulose as a marker of gastrointestinal transit time.
|
During each test visit, up to 4.5 hours after meal consumption
|
|
Appetite Sensations
Tidsramme: During each test visit, up to 4.5 hours after meal consumption
|
Appetite sensations, including hunger, fullness, desire to eat, prospective food consumption, and thirst, will be assessed using 100-mm visual analog scales during each test visit after consumption of the assigned test meal every 30 minutes.
Each visual analog scale ranges from 0 to 100 mm, with higher scores indicating a greater intensity of the rated sensation.
Higher scores are not inherently better or worse outcomes, but reflect greater hunger, fullness, desire to eat, prospective food consumption, or thirst, depending on the item.
|
During each test visit, up to 4.5 hours after meal consumption
|
|
Meal Palatability Ratings
Tidsramme: During each test visit, up to 4.5 hours after meal consumption
|
Meal palatability will be assessed using a 100-mm general labeled magnitude scale during each study visit.
The scale ranges from 0 to 100 mm, with 0 mm anchored by "most disliked sensation imaginable," 50 mm anchored by "neutral," and 100 mm anchored by "most liked sensation imaginable."
Higher scores indicate greater liking of the test meal and therefore a more favorable palatability rating.
|
During each test visit, up to 4.5 hours after meal consumption
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
24. september 2024
Primær fullføring (Faktiske)
30. april 2026
Studiet fullført (Faktiske)
30. april 2026
Datoer for studieregistrering
Først innsendt
14. mai 2026
Først innsendt som oppfylte QC-kriteriene
14. mai 2026
Først lagt ut (Faktiske)
20. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
22. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
20. mai 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB-2024-450
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
IPD-planbeskrivelse
Individual participant data will not be shared because the current IRB-approved protocol does not include a formal plan for external individual participant data sharing.
Study data will be de-identified for analysis, and identifying information will be stored separately from study data.
Code numbers linking participants to their data will be destroyed according to the approved protocol.
No information by which participants can be identified will be released or published.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Spiseatferd
-
Western University, CanadaHar ikke rekruttert ennåeTRE (Early Time Restricted Eating) med BCAA | eTRE (Early Time Restricted Eating)Canada
-
Western University, CanadaUkjenteTRE (Early Time Restricted Eating) | lTRE (Late Time Restricted Eating)Canada
-
Western University, CanadaHar ikke rekruttert ennåeTRE (Early Time Restricted Eating) | eTRE med BISC (Kort intens trappeklatring)Canada
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)FullførtStoffbruk | Familieforhold | Risikofylt seksuell atferd | Runaway Behavior
-
Marianne Lau, MD, DSci.The Ministry of Science, Technology and Innovation, DenmarkUkjentBulimia Nervosa (BN) | Binge Eating Disorder (BED) | Spiseforstyrrelse ikke spesifisert på annen måte (EDNOS)Danmark
-
SunovionFullførtAttention Deficit Hyperactivity Disorder (ADHD) | Binge-Eating Disorder DisorderForente stater